Nara Infant Formula Lawsuit Update: Injuries, Recall Status, and Legal Options

Next Review: August 29, 2026

Quick Facts

• FDA is investigating a multistate outbreak involving Nara Organics Whole Milk Organic Powdered Infant Formula.
• FDA’s July 6, 2026 update reported four confirmed infant botulism cases, four hospitalizations, and no deaths.
• Nara Organics recalled all currently marketed lots of its infant formula sold in the United States.
• Public litigation now includes a proposed consumer class action and a reported Washington infant personal-injury lawsuit.

Nara Organics recalled all cans of its Whole Milk Organic Powdered Infant Formula currently marketed in the United States after federal and state investigators linked the product to infant botulism illnesses.

FDA’s July 6 update reported four confirmed cases in California, Pennsylvania, and Washington. All four infants were hospitalized, and no deaths were reported.

A proposed consumer class action, Zetterstrom v. Nara Organics, Inc., was filed in June 2026, and a Washington family reportedly filed a separate personal-injury lawsuit against Nara Organics and Target in July 2026. These lawsuits contain allegations that have not been proven in court.

Parents and caregivers should stop using recalled Nara formula and follow FDA guidance for documenting and storing opened cans. Families whose infants were diagnosed with botulism may want to preserve formula cans, lot codes, receipts, medical records, laboratory results, and purchase information.

Latest News & Updates on Nara Infant Formula Recall Lawsuits

July 2026

July 25, 2026 – A Washington family reportedly filed a product-liability lawsuit against Nara Organics, Inc. and Target Corporation after their infant was hospitalized with infant botulism. The report states that the lawsuit alleges the recalled Nara Organics Whole Milk Organic Infant Formula was contaminated with Clostridium botulinum; those allegations have not been proven in court [1]

July 6, 2026 – FDA updated the outbreak investigation to report four confirmed infant botulism cases in California, Pennsylvania, and Washington, with four hospitalizations and no deaths. FDA also reported that Clostridium botulinum was detected in an opened formula can associated with one sick infant, while additional testing and root-cause investigation remained ongoing [2]

June 2026

June 14, 2026 – A proposed consumer class action, Zetterstrom v. Nara Organics, Inc., No. 1:26-cv-05026, was filed in the U.S. District Court for the Southern District of New York. The Justia docket identifies the case as a product-liability action and lists the filing of a complaint against Nara Organics, Inc. [3]

June 13, 2026 – FDA posted Nara Organics’ recall of all lots of Nara Organics Whole Milk Organic Powdered Infant Formula sold in the United States after FDA and CDC provided information about three infant botulism cases involving infants who had consumed Nara formula. The company’s recall announcement stated that the product was distributed nationally through Target retail stores, Target.com, and Nara.com between July 2025 and June 2026 [4]

What Is the Nara Infant Formula Recall?

The Nara infant formula recall involves Nara Organics Whole Milk Organic Powdered Infant Formula. Nara Organics recalled all cans of the product currently on the U.S. market.

The recalled formula was sold nationwide through Target stores, Target.com, and Nara.com between July 2025 and June 2026. FDA’s outbreak page states that the product was not distributed outside the United States.

The FDA-posted recall announcement identified two can sizes: 700g cans with UPC 860013251901 and 400g cans with UPC 860013251918. Parents and caregivers should also check lot codes, use-by dates, purchase records, and any FDA or company updates.

The initial June 13 recall announcement identified three lot codes associated with formula consumed by the first three reported infants: 709125280E14F2, 709125288E14F2, and 708125174E14F2. Nara’s recall covered all lots currently marketed in the United States, not only those three exposure lots.

What Is the Current Outbreak Status?

FDA’s July 6 update reported a multistate outbreak of four confirmed infant botulism illnesses from California, Pennsylvania, and Washington. The illness-onset period ran from April to May 2026, with the last reported illness onset on May 31, 2026.

All four reported infants were hospitalized. FDA reported no deaths as of the July 6 update.

FDA also reported that Clostridium botulinum was detected in an opened can of Nara formula associated with one sick infant. This later FDA update should be distinguished from Nara’s June 13 statement that the formula had not tested positive at that time.

FDA’s investigation remained ongoing in July 2026. FDA stated that whole genome sequencing and additional testing, including testing of unopened product samples, were still in progress.

What Is Infant Botulism?

Infant botulism is a rare but serious illness that can occur when Clostridium botulinum spores colonize an infant’s intestinal tract and produce botulinum toxin. The condition can cause progressive weakness and potentially life-threatening breathing problems.

CDC lists infant symptoms that may include constipation, poor feeding, drooping eyelids, sluggish pupils, flattened facial expression, diminished sucking and gag reflexes, weak or altered cry, respiratory difficulty, and possible respiratory arrest. Parents should seek immediate medical care if an infant who consumed recalled formula develops concerning symptoms [5].

Infant botulism is treated differently from some other forms of botulism. CDC clinical information identifies BabyBIG as the treatment released after consultation with the California Department of Public Health Infant Botulism Treatment and Prevention Program [6].

Reported Risks or Injuries

The reported risk is infant botulism after consumption of contaminated powdered infant formula. FDA’s current outbreak update reports four confirmed cases, four hospitalizations, and no deaths.

Infant botulism may cause serious neurological symptoms and breathing difficulties. Severe cases may require hospitalization, specialist consultation, intensive monitoring, respiratory support, and BabyBIG treatment.

The FDA-posted June recall announcement stated that three infants had consumed Nara formula and were hospitalized and treated with BabyBIG. FDA’s July update later added a fourth confirmed case and reported detection of Clostridium botulinum in an opened can associated with one sick infant.

Parents and caregivers should document symptoms, diagnosis, treatment, hospital records, BabyBIG treatment information, formula lot codes, purchase records, and communications with healthcare providers or public health officials.

How Does the Problem Occur, and Who May Be Liable?

The alleged problem can occur if powdered infant formula contaminated with Clostridium botulinum spores is consumed by an infant. In the immature infant gut, spores can colonize and produce toxin that causes infant botulism.

A legal investigation may examine ingredient suppliers, milk powder sourcing, manufacturing records, environmental testing, lot records, sanitation records, distribution records, Target sales records, recall timing, FDA communications, consumer complaints, and post-recall testing. These records may help determine how contamination occurred and whether appropriate food-safety controls were followed.

Potentially responsible parties may include Nara Organics, manufacturers, ingredient suppliers, distributors, retailers, Target, online sellers, or other companies involved in producing, testing, distributing, selling, or warning about the recalled formula. Liability depends on exposure evidence, diagnosis, causation, medical records, damages, available defendants, and applicable state law.

A recall, outbreak investigation, or lawsuit filing does not automatically prove that any company is legally responsible for a specific illness. Each family’s claim requires individualized review of formula exposure, medical evidence, timing, product testing, damages, and filing deadlines.

Who May Be Affected?

Families may be affected if an infant consumed Nara Organics Whole Milk Organic Powdered Infant Formula purchased from Target stores, Target.com, or Nara.com between July 2025 and June 2026. Infants under one year old are the relevant risk group for infant botulism.

Parents may also be affected if a child required hospitalization, BabyBIG treatment, respiratory support, follow-up care, physical therapy, or other medical services. Household costs may include travel, missed work, caregiving, lodging, and out-of-pocket medical expenses.

FDA recommends that parents and caregivers stop using recalled formula immediately. FDA also advises families to photograph and record the lot number and use-by date if formula remains in the home.

If an infant has symptoms after consuming Nara formula, FDA says families should consider retaining opened cans because health departments may want to test the product. Opened cans should be labeled “DO NOT USE” and stored safely away from items used to feed the baby.

Do I Qualify?

• Did your infant consume recalled Nara Organics Whole Milk Organic Powdered Infant Formula?
• Was your infant diagnosed with infant botulism or treated for symptoms consistent with infant botulism?
• Did your infant require hospitalization, BabyBIG treatment, respiratory support, or follow-up medical care?
• Can you document the formula purchase, lot code, use-by date, medical records, laboratory results, or public-health communications?

An individual legal review can determine whether the exposure evidence, diagnosis, medical records, damages, potential defendants, and filing deadlines support a possible claim.

Do I Have a Nara Infant Formula Recall Lawsuit?

If your infant developed botulism after consuming recalled Nara Organics infant formula, you may have legal options. Contact Schmidt & Clark for a free case review.

Start My Free Case Review

Important Legal Actions or Recalls

Potential Compensation

Potential compensation may include emergency care, hospitalization, BabyBIG treatment, diagnostic testing, respiratory support, specialist care, follow-up appointments, physical therapy, and future medical expenses.

Additional damages may include pain and suffering, parental lost wages, travel expenses, caregiving costs, out-of-pocket expenses, long-term developmental care, and other documented losses. The specific damages available depend on the diagnosis, treatment, documentation, causation evidence, state law, and the facts of the claim.

Compensation amounts vary by case. Past results do not guarantee future outcomes.

Legal Process Overview

Step 1: Free case review. The review begins with what formula was used, when it was purchased, when symptoms began, and whether infant botulism was diagnosed. Formula cans, lot-code photos, Target or Nara receipts, medical records, hospital records, and public-health communications may help establish the basic facts.

Step 2: Investigation. The investigation may examine recalled-product identity, lot codes, purchase records, exposure timing, FDA updates, medical records, lab results, BabyBIG treatment, public-health testing, distribution records, and potential defendants. Attorneys may also review whether the infant’s illness timing and diagnosis match the outbreak investigation.

Step 3: Filing. A supported claim may allege negligence, strict product liability, breach of warranty, failure to warn, supplier liability, retailer liability, or other food-safety theories. Filing occurs only when the evidence and applicable law support a claim against one or more responsible parties.

Step 4: Discovery/negotiation. The parties may exchange production records, ingredient-supplier records, testing results, sanitation records, distribution documents, recall communications, medical records, expert opinions, and testimony. Negotiations may focus on exposure proof, causation, hospitalization, treatment costs, long-term effects, lost wages, and family losses.

Step 5: Resolution. A case may resolve through settlement, dismissal, court ruling, or trial. The outcome depends on product tracing, medical documentation, causation evidence, damages, defenses, available defendants, insurance issues, and applicable law.

Frequently Asked Questions About the Nara Infant Formula Recall Lawsuit

What is the Nara Infant Formula Recall Lawsuit?

The phrase refers to potential legal claims involving infants who developed botulism after consuming recalled Nara Organics Whole Milk Organic Powdered Infant Formula. Public litigation includes a proposed consumer class action and a reported Washington personal-injury lawsuit.

Why was Nara infant formula recalled?

Nara Organics recalled all U.S. cans of its infant formula after FDA and CDC provided information about infant botulism cases involving infants who consumed Nara formula. FDA later reported four confirmed cases and detection of Clostridium botulinum in an opened can associated with one sick infant.

How many Nara infant formula botulism cases have been reported?

FDA’s July 6 update reported four confirmed infant botulism cases in California, Pennsylvania, and Washington. FDA reported four hospitalizations and no deaths.

Which Nara formula products are recalled?

The recall covers all cans of Nara Organics Whole Milk Organic Powdered Infant Formula currently marketed in the United States. The FDA-posted recall identified 700g cans with UPC 860013251901 and 400g cans with UPC 860013251918.

Has a Nara infant formula class action been filed?

Yes. Justia identifies Zetterstrom v. Nara Organics, Inc., No. 1:26-cv-05026, as a product-liability case filed in the Southern District of New York. The docket entry identifies a complaint against Nara Organics, Inc.

Can I file a Nara Infant Formula Recall Lawsuit if my baby was hospitalized?

Possibly. A legal review may consider whether the infant consumed recalled Nara formula, whether infant botulism was diagnosed, whether hospitalization or BabyBIG treatment occurred, and what evidence documents exposure and damages. Eligibility depends on the facts and applicable state law.

What evidence could support a Nara infant formula claim?

Helpful evidence may include formula cans, lot-code photos, use-by-date photos, receipts, Target order records, Nara order records, medical records, laboratory results, BabyBIG treatment records, public-health communications, and witness information. If an opened can remains available, FDA guidance says health departments may want to test it if an infant develops symptoms.

What should parents do with recalled Nara formula?

Parents and caregivers should stop using recalled formula immediately. FDA recommends photographing and recording the lot number and use-by date, and if an infant has symptoms, considering retention of opened cans for possible health-department testing.

References

1. https://www.morningstar.com/news/pr-newswire/20260725sf11603/washington-family-sues-nara-organics-and-target-after-their-infant-was-hospitalized-with-botulism-from-recalled-organic-formula
2. https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-powdered-infant-formula-june-2026
3. https://dockets.justia.com/docket/new-york/nysdce/1%3A2026cv05026/666259
4. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/nara-organics-recalls-all-lots-nara-infant-formula-because-possible-health-risk
5. https://www.cdc.gov/botulism/signs-symptoms/index.html
6. https://www.cdc.gov/botulism/hcp/clinical-overview/infant-botulism.html